DelveInsight’s “Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graft Versus Host Disease market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Graft Versus Host Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Graft Versus Host Disease (GvHD): An Overview
According to the National Cancer Institute (NCI), Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.
GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD and occurs usually in the initial 2-3 months after transplantation. Chronic GVHD occurs around 3-4 months after the transplantation has happened and has more diverse complications. Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four-point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).
Graft Versus Host Disease (GvHD) Market Key Facts
-
In 2020, the 7MM reported 24,000+ allogeneic cases. The United States accounted for 9,800+ allogeneic cases in 2020, representing the highest percentage of all allo-HSCT in the 7MM.
-
GvHD is categorized into two types: aGvHD and cGvHD. In 2020, acute GvHD cases accounted for 11,600+, while chronic cases accounted for 7,800+. In the 7MM, the aGvHD and cGvHD cases are expected to rise by 2032.
-
Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,900+ cases in 2020.
-
The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,900+ in first-line.
-
As per Orphanet, about 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute Graft versus host disease (GVHD). And about 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.
Graft Versus Host Disease (GvHD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Graft Versus Host Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Graft Versus Host Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Graft Versus Host Disease (GvHD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Graft Versus Host Disease (GvHD) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft Versus Host Disease market or expected to get launched during the study period. The analysis covers the Graft Versus Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graft Versus Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Graft Versus Host Disease Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market
Key Companies in the Graft Versus Host Disease (GVHD) Market include:
-
Medac
-
Takeda
-
Xenikos
-
MaaT Pharma
-
CSL Behring
-
Syndax Pharmaceutical
-
Kadmon Corporation
-
Mesoblast/Osiris Therapeutics
-
Regimmune Corporation
-
OncoImmune/Merck (MSD)
-
ElsaLys Biotech/Mediolanum Farmaceutici
And many others.
Graft Versus Host Disease (GvHD) Therapies covered in the report includes:
-
MaaT013
-
RGI-2001
-
MK-7110 (CD24Fc)
-
T-Guard
-
CSL 964 AAT (Zemaira)
-
Obnitix (MC0518)
-
KD025 (Belumosudil)
-
Leukotac (Inolimomab)
-
Axatilimab (SNDX-6532)
-
Entyvio (Vedolizumab;MLN0002)
-
Ryoncil (Remestemcel-L; Prochymal)
And many others.
Apart from the drugs mentioned above, many other companies are trying their hands in this area to find the best prophylaxis or curative option to provide lifetime relief to the patient pool suffering or who might suffer from GvHD in the future.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Graft Versus Host Disease Competitive Intelligence Analysis
4. Graft Versus Host Disease Market Overview at a Glance
5. Graft Versus Host Disease Disease Background and Overview
6. Graft Versus Host Disease Patient Journey
7. Graft Versus Host Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Graft Versus Host Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Graft Versus Host Disease Unmet Needs
10. Key Endpoints of Graft Versus Host Disease Treatment
11. Graft Versus Host Disease Marketed Products
12. Graft Versus Host Disease Emerging Drugs and Latest Therapeutic Advances
13. Graft Versus Host Disease Seven Major Market Analysis
14. Attribute Analysis
15. Graft Versus Host Disease Market Outlook (In US, EU5, and Japan)
16. Graft Versus Host Disease Access and Reimbursement Overview
17. KOL Views on the Graft Versus Host Disease Market
18. Graft Versus Host Disease Market Drivers
19. Graft Versus Host Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market
Other Trending Healthcare Reports By DelveInsight
Graft Versus Host Disease (GVHD) Pipeline Insights
Graft versus host disease (GVHD) Pipeline Insight, 2022 report by DelveInsight, outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/